A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).
Stephen J FreedlandJenifer AllenAubrey JarmanTaofik OyekunleAndrew J ArmstrongJudd W MoulHoward M SandlerEdwin M PosadasDana LevinEmily WigginsLauren E HowardYuan WuPao-Hwa LinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Among BCR patients, LCD induced weight loss and metabolic benefits with acceptable safety without affecting PSADT, suggesting LCD does not adversely affect prostate cancer growth and is safe. Given exploratory findings of longer PSADT, larger studies testing LCD on disease progression are warranted.
Keyphrases
- prostate cancer
- radical prostatectomy
- weight loss
- end stage renal disease
- newly diagnosed
- randomized controlled trial
- ejection fraction
- peritoneal dialysis
- acute lymphoblastic leukemia
- bariatric surgery
- prognostic factors
- type diabetes
- high glucose
- body mass index
- drug induced
- oxidative stress
- patient reported outcomes
- benign prostatic hyperplasia
- case control